Literature DB >> 10716152

Giant cell tumors of soft tissue: a clinicopathologic study of 18 benign and malignant tumors.

J X O'Connell1, B M Wehrli, G P Nielsen, A E Rosenberg.   

Abstract

Primary giant cell tumors (GCTs) of soft tissue resembling osseous GCTs are uncommon but distinct entities. Malignant GCTs of soft tissue have been designated giant cell malignant fibrous histiocytomas; however, there is scant data regarding benign GCTs of soft tissue. Eleven benign and seven malignant GCTs of soft tissue were identified from the authors' consultation files and the surgical pathology files of the Vancouver General Hospital and Massachusetts General Hospital. The tumors occurred in adults (eight men, 10 women; age range, 25-89 years; mean age, 54 years) in the extremities (n = 14) and in the trunk, abdomen, and pelvis (n = 4). In each patient the skeleton was normal and there was no history of prior osseous GCT. Tumors ranged in size from 0.8 to 9.0 cm. Eleven occurred in the superficial soft tissue and seven occurred in deep soft tissue. Grossly they were circumscribed and frequently hemorrhagic. Cystic change was present in seven tumors. Nine tumors were partially surrounded by a shell of reactive bone. In all tumors, multinucleated osteoclast-like giant cells were distributed uniformly and evenly among mononuclear cells. The histologically benign GCTs of soft tissue were identical to typical osseous GCTs. The mononuclear cells in these tumors lacked nuclear atypia or pleomorphism, and the mitotic rate within this population was low (mean, three mitoses per 10 high-power fields [HPF]). In the malignant GCTs of soft tissue, the mononuclear cells exhibited anisocytosis, nuclear atypia, pleomorphism, and readily detectable mitoses including atypical forms (mean, 25 mitoses per 10 HPF). None of the benign or malignant tumors exhibited neoplastic bone production. The benign and malignant GCTs of soft tissue demonstrated a similar immunohistochemical staining profile to GCT of bone ( 12 tumors examined), exhibiting strong positive staining for CD68 within multinucleated osteoclastlike cells, and focal staining of mononuclear cells for CD68, Ham 56, and smooth muscle actin. All tumors were treated by surgical resection. Follow-up information is available for 15 patients (range, 0-108 months). No benign tumor has recurred or metastasized. Of the four patients with malignant tumors for whom follow-up information is available, one died of metastatic disease at 13 months and one developed a local recurrence at 84 months but is alive, apparently free of disease after additional excisional surgery. Primary GCTs of soft tissue are distinctive neoplasms that, like osseous GCTs, exhibit a wide clinicopathologic spectrum. These neoplasms should be distinguished from other giant cell-rich soft-tissue tumors with which they may be confused.

Entities:  

Mesh:

Year:  2000        PMID: 10716152     DOI: 10.1097/00000478-200003000-00007

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  29 in total

1.  Giant cell tumor of soft tissue is genetically distinct from its bone counterpart.

Authors:  Jen-Chieh Lee; Cher-Wei Liang; Christopher Dm Fletcher
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

2.  Giant cell tumor of soft tissue: a case report with emphasis on MR imaging.

Authors:  Moon Young Lee; Won-Hee Jee; Chan Kwon Jung; Ie Ryung Yoo; Yang-Guk Chung
Journal:  Skeletal Radiol       Date:  2015-04-03       Impact factor: 2.199

3.  Study of 7 Cases of Giant Cell Tumor of Soft Tissue.

Authors:  Kailash Chand; R K Bhardwaj; T J Rappai
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  Primary giant cell tumor of soft tissue: fluid-fluid levels at MRI (2010:3b).

Authors:  Ana Rosa Meana Moris; Pedro García Gonzalez; Eduardo Fuente Martin; Carmen Gonzalez Suarez; Luis Moro Barrero
Journal:  Eur Radiol       Date:  2010-04-30       Impact factor: 5.315

5.  Unusual aggressive course of a giant cell tumor of soft tissue during immunosuppressive therapy.

Authors:  Florian Grabellus; Friederike von Winterfeld; Sien-Yi Sheu; Klaus A Metz; Klaus Jahnke; Kurt W Schmid
Journal:  Virchows Arch       Date:  2006-04-05       Impact factor: 4.064

6.  Role of the VEGF-Flt-1-FAK pathway in the pathogenesis of osteoclastic bone destruction of giant cell tumors of bone.

Authors:  Yoshihiro Matsumoto; Yuko Okada; Jun-Ichi Fukushi; Satoshi Kamura; Toshifumi Fujiwara; Keiichiro Iida; Mihoko Koga; Shuichi Matsuda; Katsumi Harimaya; Akio Sakamoto; Yukihide Iwamoto
Journal:  J Orthop Surg Res       Date:  2010-11-09       Impact factor: 2.359

7.  An eggshell-like mineralized recurrent lesion in the popliteal region after treatment of giant cell tumor of the bone with denosumab.

Authors:  Keisuke Akaike; Yoshiyuki Suehara; Tatsuya Takagi; Kazuo Kaneko; Tsuyoshi Saito
Journal:  Skeletal Radiol       Date:  2014-07-24       Impact factor: 2.199

8.  Osteoclast-like giant cell tumor arising in the soft tissue of the breast: report of a case.

Authors:  Laszlo Romics; Elizabeth A Mallon; Robin Reid; Carolyn M Cordiner; Julie C Doughty
Journal:  Surg Today       Date:  2009-01-08       Impact factor: 2.549

9.  Giant cell tumor of soft tissue: a case with atypical US and MRI findings.

Authors:  Sang Bu An; Jung-Ah Choi; Jin-Haeng Chung; Joo Han Oh; Heung Sik Kang
Journal:  Korean J Radiol       Date:  2008 Sep-Oct       Impact factor: 3.500

10.  [Giant cell tumors of soft tissue arising in surgical scars].

Authors:  F Grabellus; S-Y Sheu; B Schmidt; F von Winterfeld; B Schoenfeld; G Taeger; U Hillen; K W Schmid
Journal:  Pathologe       Date:  2009-09       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.